Philips North America is suing a well-known Pennsylvania testing lab, attempting to shift blame for one of the nation’s largest medical device recalls onto its contractor, PSN Labs of Erie.

Philips claims the lab carried out tests that were inaccurate and overstated the risk of the company’s once popular breathing machines, which were pulled off the shelves in 2021 in a massive recall.

“PSN committed numerous egregious errors in its testing and associated analysis,” Philips said in its lawsuit, which is part of the ongoing litigation in federal court in Pittsburgh over the device maker’s CPAP machines and ventilators.

“Philips [Respironics] has spent hundreds of millions of dollars toward this recall and would have pursued a different and more focused recall had PSN not made its serious mistakes and greatly overestimated the potential threat to patients,” the lawsuit states.

Advertise with us

Philips, which maintains the foam in its breathing machines “was not toxic,” agreed to pay $1 billion to settle personal injury claims earlier this year and is banned from selling new devices in the United States under a consent decree with the Food and Drug Administration.

The company, with two massive factories near Pittsburgh, plans to move manufacturing outside of Pennsylvania, and will soon abandon its corporate office in Pittsburgh.

PSN says it will vigorously fight the company’s claims.

“I am aware of the allegations that Philips has against PSN Labs, and can state unequivocally that the claims are without merit and severely distort the facts,” Michael Alabran, president of PSN Labs, said in a statement to the Post-Gazette.

“I cannot comment in greater detail given the ongoing litigation, but can assure you that PSN Labs has made it our mission to be a source of truth in the industry and to make patient safety our utmost priority.”

Advertise with us

A Post-Gazette and ProPublica investigation last year found that Philips withheld thousands of complaints related to the breakdown of foam in its machines for years, despite federal law that requires the reports be filed in 30 days.

Philips is now the target of a criminal investigation by the Department of Justice.

Since the recall, the FDA reports that it has received at least 561 reports of deaths associated with the company's breathing devices.

PSN was one of several testing companies Philips used to check the safety of its foam, which the company’s own public reports showed could break down in the devices, releasing potentially harmful chemicals into the masks of patients.

According to the lawsuit, PSN’s findings were an inaccurate “outlier.” PSN misidentified certain chemicals, including ozone and dimethyl diazene, that were not present in the foam, Philips said. The lab also overstated the risk of the chemical phenol.

Advertise with us

“PSN tried to cover up its own mistakes and doubled down on its incorrect conclusion that the foam was unsafe in order to divert the focus away from its own errors,” the lawsuit states.

Philips said it only learned of the errors two years after the recall when it obtained raw data from PSN by subpoena.

However, confidential records obtained by the Post-Gazette showed that at least two other labs had found that the foam in the devices exceeded safety thresholds before PSN carried out its own tests on the material.

As far back as 2008, a testing lab had found the foam to be cytotoxic, the ability of chemicals to destroy cells and increase the risk of organ damage, according to the internal records.

A series of damaging findings from multiple labs and Philips’ own engineers led to extensive fighting and resignations over safety issues within the company, the Post-Gazette found.

Advertise with us

Philips has sought to deflect blame for the recall before. It sued SoClean, which makes an ozone cleaner used to disinfect CPAPs, alleging the product made the foam break down faster. (The FDA has said that the machines themselves, not the cleaners, presented “unreasonable risk to patients.”). The case is still pending.

Earlier this year, Philips announced it was cutting hundreds of manufacturing jobs and abandoning its Pittsburgh offices. It is unclear if they will resume selling the devices in the U.S.

Philips and the FDA declined to comment on where the company is moving.

“The FDA generally cannot publicly disclose confidential commercial information,” the agency said in a response to detailed questions from the Post-Gazette. “The FDA will continue to use all available resources and tools to oversee the safety and quality of FDA-regulated products to protect public health.”

While Philips has announced that the recalled machines will not cause long-term harm in patients, the FDA has rejected that claim, saying the devices can cause serious injuries and even death.

Test results by the company have also been challenged by the FDA, which has said the tests are not adequate.